Heparin resistance and the potential impact on maintenance of therapeutic coagulation

European Journal of Anaesthesiology

Volumn 24, Issue SUPPL. 40, 2007, Pages 37-58

  Despotis, G J ^a   Avidan, M ^a   Levy, J H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Antithrombin; Bleeding; Cardiac surgery; Disseminated intravascular consumption; Hemostatic system; Heparin resistance; Herapin

Indexed keywords

ANTITHROMBIN III; ARGATROBAN; DALTEPARIN; DERMATAN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRUGEN; HIRULOG; NITRIC OXIDE; PROSTACYCLIN; PROTAMINE; WARFARIN;

ADJUVANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FLUOROMETRY; HEART SURGERY; HUMAN; INFORMATION PROCESSING; INHIBITION KINETICS; LOADING DRUG DOSE; MEDLINE; MONITORING; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PROSPECTIVE STUDY; PUBLICATION; REVIEW; SINGLE DRUG DOSE; TITRIMETRY; TRANSFUSION;

EID: 34447512905     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021507000592     Document Type: Review

References (202)

1. Hardy JF, Perrault J, Tremblay N et al. The stratification of cardiac surgical procedures according to use of blood products: a retrospective analysis of 1480 cases. Can J Anaesth 1991; 38: 511-517.
2. Despotis GJ, Santoro SA, Spitznagel E et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271-279.
3. Khuri SF, Wolfe JA, Josa M et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104: 94-107.
4. Despotis GJ, Filos KS, Zoys TN et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13-21.
5. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697.
6. Gammie JS, Zenati M, Kormos RL et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998; 65: 465-469.
7. Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979; 77: 427-435.
8. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980; 286: 456-460.
9. Boisclair MD, Lane DA Philippou H et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993; 82: 3350-3357.
10. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995; 59: 901-907.
11. Holloway DS, Summaria L, Sandesara J et al. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988; 59: 62-67.
12. Yoshihara H, Yamamoto T, Mihara H. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res 1985; 37: 503-512.
13. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 828-833.
14. Stibbe J, Kluft C, Brommer EJ et al. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382.
15. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
16. Khuri SF, Valeri CR, Loscalzo J et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995; 60: 1008-1014.
17. John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-822.
18. Cobel-Geard RJ, Hassouna HI. Interaction of protamine sulfate with thrombin. Am J Hematol 1983; 14: 227-233.
19. Shigeta O, Kojima H, Hiramatsu Y et al. Low dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354-360.
20. Mochizuki T, Olson PJ, Ramsay JG, Szlam F, Levy JH. Protamine reversal of heparin affects platelet function aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-785.
21. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 1997; 86: 1382-1386.
22. Wachtfogel YT, Kucich U, Greenplate J et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-330.
23. Clauss M, Grell M, Fangmann C et al. Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors. FEBS Lett 1996; 390: 334-338.
24. van der Poll T, Jansen PM, Van Zee KJ et al. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996; 88: 922-927.
25. Despotis GJ, Joist JH, Hogue CW et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902-908.
26. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb.Haemost 1993; 70: 253-258.
27. Slaughter TF, LeBleu TH Douglas Jr JM et al. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520-526.
28. Menges T, Wagner RM, Welters I et al. The role of the protein Cthrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis. J Cardiothorac Vasc Anesth 1996; 10: 482-489.
29. Hunt BJ, Parratt RN, Segal HC et al. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998; 65: 712-718.
30. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Philadelphia 1994, pp 1023-1063.
31. Gralnick HR, Fischer RD. The hemostatic response to open-heart operations. J Thorac Cardiovasc Surg 1971; 61: 909-915.
32. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-834.
33. Milam JD, Austin SF, Martin RF, Keats AS, Cooley DA. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions. Am J Clin Pathol 1981; 76: 155-162.
34. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65: 32-40.
35. Lu H, Soria C, Cramer EM et al. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 1991; 77: 996-1005.
36. Lu H, Soria C, Commin PL et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-637.
37. Dacey LJ, Munoz JJ, Baribeau YR et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998; 133: 442-447.
38. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-1046.
39. van de Watering LM, Hermans J, Houbiers JG et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97: 562-568.
40. Bray B, Lane DA, Freyssinet JM, Pejler G, Lindahl U. Antithrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J 1989; 262: 225-232.
41. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-1214.
42. Tollefson FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemost 1985; 86: 385-391.
43. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin- antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
44. Choay J, Petitou M, Lormeau JC et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
45. Hirsh J, Raschke R, Warkentin TE et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995; 108: 258S-275S.
46. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23(Suppl 1): 103-106.
47. Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168.
48. Sobel M, McNeill PM, Carlson PL et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793.
49. Suzuki K, Nishioka J, Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta 1979; 585: 416-426.
50. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm 1979; 7: 331-354.
51. de Swart MAC, Nijmeyer B, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258.
52. Estes JW, Poulin PF. Pharmacokinetics of heparin: Distribution and elimination. Thrombos Diathes Haemorrh (Stuttg) 1975; 33: 26-37.
53. Hull RD, Raskob GE, Hirsh J et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
54. Barzu T, van Rijn JL, Petitou M, Tobelem G, Caen JP. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601-609.
55. Boneu B, Caranobe C, Cadroy Y et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988; 14: 18-27.
56. Despotis GJ, Joist JH, Hogue CW et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 46-54.
57. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
58. Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas DG. Response of kaolin ACT to heparin: Evaluation with an automated assay and higher heparin concentrations. Ann Thorac Surg 1996; 61: 795-799.
59. Schwartz RS, Bauer KA, Rosenberg RD et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 1989; 87: 53-60.
60. Wolk LA, Wilson RF, Burdick M et al. Changes in antithrombin, antiplasmin, and plasminogen during and after cardiopulmonary bypass. Am Surgeon 1985; 51: 309-313.
61. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995; 58: 799-805.
62. Zaidan JR, Johnson S, Brynes R, Monroe S, Guffin AV. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986; 65: 377-380.
63. Irani MS. Antithrombin concentrates in heparin-resistant cardiopulmonary bypass patients. Clin Appl Thromb Hemostas 1996; 2: 103-106.
64. Dietrich W, Spannagl M, Schramm W et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505-514.
65. Matthai WHJ, Kurnik PB, Groh WC, Untereker WJ, Siegel JE. Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol 1999; 33: 1248-1256.
66. Esposito RA, Culliford AT, Colvin SB et al. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983; 85: 346-353.
67. Wu HF, Lundblad RL, Church FC. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995; 85: 421-428.
68. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986.
69. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-291.
70. Teoh KH, Young E, Bradley CA, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation 1993; 88: 420-425.
71. Lane DA. Heparin binding and neutralization proteins. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties. Clinical Application. CRC Press, Boca Raton, Fla 1989, p 362.
72. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. J Biol.Chem 1987; 262: 12247-12253.
73. Thomas DP, Barrowcliffe TW, Johnson EA. The influence of tissue source, salt and molecular weight and heparin activity. Scand J Haematol Suppl 1980; 36: 40-49.
74. Anderson EF. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 1986; 64: 504-507.
75. Cloyd GM, D' Ambra MN, Akins CW. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1987; 94: 535-538.
76. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57: 1211-1216.
77. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001; 92: 66-71.
78. Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion 2006; 21: 99-103.
79. Ranucci M, Isgro G, Cazzaniga A et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204.
80. Kopriva CJ. The activated coagulation time (ACT). In: Ellison N, Jobes DR, eds. Effective hemostasis in cardiac surgery. W. B. Saunders Co., Philadelphia 1988, pp 155-162.
81. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg 1988; 67: 469-472.
82. Despotis GJ, Summerfield AL, Joist JH et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-1082.
83. Jobes DR, Schwartz AJ, Ellison N et al. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1980; 31: 161-166.
84. Cohen EJ, Cameriengo LJ, Dearing JP. Activated clotting times and cardiopulmonary bypass. I. The effect of hemodilution and hypothermia upon activated clotting time. JECT 1980; 12: 139-141.
85. Stenbjerg S, Berg E, Albrechtsen OK. Heparin levels and activated clotting time (ACT) during open heart surgery. Scand J Haematol 1981; 26: 281-284.
86. Culliford AT, Gitel SN Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Annals of Surgery 1981; 193: 105-111.
87. Gravlee GP. Anticoagulation for Cardiopulmonary bypass. In: Gravlee GP, ed. Cardiopulmonary bypass: Principles and Practice. Williams & Wilkens, Baltimore 1993, pp 340-380.
88. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-398.
89. Moliterno DJ, Califf RM, Aguirre FV et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-562.
90. Wang JS, Lin CY, Hung WT, Karp RB. Monitoring of heparin-induced anticoagulation with kaolin- activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992; 77: 1080-1084.
91. Wendel HP, Heller W, Gallimore MJ et al. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coag Fibrinol 1993; 4: 41-45.
92. Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 211-212.
93. Wang JS, Lin CY, Karp RB. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg 1994; 79: 9-13.
94. Najman DM, Walenga JM, Fareed J, Pifarre R. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Ann Thorac Surg 1993; 55: 662-666.
95. Umlas J, Gauvin G, Taff R. Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay. Ann Thorac Surg 1984; 37: 301-303.
96. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990; 49: 440-444.
97. Despotis GJ, Levine V, Joiner-Maier D, Joist JH. A comparison between continuous infusion versus standard bolus administration of heparin based on monitoring in cardiac surgery. Blood Coagul Fibrinolysis 1997; 8: 419-430.
98. Gravlee GP, Rogers AT, Dudas LM et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393-401.
99. Gravlee GP, Haddon WS, Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990; 99: 518-527.
100. Harloff M, Taraskiewicz D, Fotouhi C. Comparison study of the hepcon system four and the hemostasis management system. Perfusion 1991; 6: 297-301.
101. Saleem A, Shenaq SS, Yawn DH et al. Heparin monitoring during cardiopulmonary bypass. Ann Clin Lab Sci 1984; 14: 474-479.
102. Wahr JA, Yun JH, Yang VC et al. A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electro-chemical sensor. J Cardiothorac Vasc Anesth 1996; 10: 447-450.
103. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg 1996; 170: 611-613.
104. Despotis GJ, Joist JH, Joiner-Maier D et al. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg 1995; 59: 106-111.
105. Hardy JF, Belisle S, Robitaille D et al. Measurement of heparin concentration in whole blood with the hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996; 112: 154-161.
106. Despotis GJ, Levine V, Joist HJ, Santoro SA, Mendeloff E. Multiple episodes of thrombosis with biventricular support devices with inadequate anticoagulation and evidence of accelerated intravascular coagulation. J Thorac Cardiovasc Surg 1997; 113: 419-422.
107. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674-684.
108. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685-689.
109. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 36-45.
110. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg 1977; 24: 170-173.
111. Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1977; 73: 780-782.
112. Roth JA, Cukingnan RA, Scott CR. Use of activated coagulation time to monitor heparin during cardiac surgery. Ann Thorac Surg 1979; 28: 69-72.
113. Papaconstantinou C, Radegran K. Use of the activated coagulation time in cardiac surgery. Effects on heparin-protamine dosages and bleeding. Scand J Thorac Cardiovasc Surg 1981; 15: 213-215.
114. Jumean HG, Sudah F. Monitoring of anticoagulant therapy during open-heart surgery in children with congenital heart disease. Acta Haematol 1983; 70: 392-395.
115. Niinikoski J, Laato M, Laaksonen V, Jalonen J, Inberg MV. Use of activated clotting time to monitor anticoagulation during cardiac surgery. Scand J Thora Cardiovasc Surg 1984; 18: 57-61.
116. Lefemine AA, Lewis M. Activated clotting time for control of anticoagulation during surgery. Am Surg 1985; 51: 274-278.
117. Preiss DU, Schmidt-Bleibtreu H, Berguson P, Metz G. Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique. Klin Wochenschr 1985; 63: 252-256.
118. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980; 79: 97-102.
119. Dearing JP, Bartles DM, Stroud MR, Sade RM. Activated clotting times versus protocol anticoagulation management. J Extra Corpor Tech 1998; 15: 17-19.
120. Sakurada T, Kikuchi Y, Koushima R et al. Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system. Nippon Kyobu Geka Gakkai Zasshi 1997; 45: 836-840.
121. Boldt J, Schindler E, Osmer C et al. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994; 73: 639-644.
122. Okita YO, Takamoto S, Ando M et al. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization. Circulation 1997; 96: 376-381.
123. Fernandez F, N'guyen P, Van Ryn J et al. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495.
124. Carr Jr. ME, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin antiplatelet effects. Thromb Res 1994; 75: 617-630.
125. John LC, Rees GM, Kovacs IB. Different anticoagulants and platelet reactivity in cardiac surgical patients. Ann Thorac Surg 1993; 56: 899-902.
126. Dietrich W, Dilthey G, Spannagl M, Richter JA. Warfarin pretreatment does not lead to increased bleeding tendency during cardiac surgery. J Cardiothora Vasc Anesth 1995; 9: 250-254.
127. Morris CD, Vega JD, Levy JH et al. Warfarin therapy does not increase bleeding in patients undergoing heart transplantation. Ann Thorac Surg 2001; 72: 714-718.
128. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 1984; 37: 466-468.
129. Van Norman GA, Gernsheimer T, Chandler WL, Cochran RP, Spiess BD. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth 1997; 11: 760-763.
130. Conley JC, Plunkett PF. Antithrombin III in cardiac surgery: an outcome study. J Extra Corpor Technol 1998; 30: 178-183.
131. Kanbak M. The treatment of heparin resistance with Antithrombin III in cardiac surgery. Can J Anaesth 1999; 46: 581-585.
132. Williams MR, D'Ambra AB, Beck JR et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-877.
133. Heller EL, Paul L. Anticoagulation management in a patient with an acquired antithrombin III deficiency. J Extra Corpor Technol 2001; 33: 245-248.
134. Lemmer Jr JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213-217.
135. Levy JH, Despotis GJ, Szlam F et al. Recombinant Human Transgenic Antithrombin in Cardiac Surgery: A Dose-finding Study. Anesthesiology 2002; 96: 1095-1102.
136. Koster A, Fischer T, Gruendel M et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 2003; 17: 171-175.
137. Avidan MS, Levy JH, Scholz J et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-284.
138. Avidan MS, Levy JH, Van Aken H et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-113.
139. Shanberge JN, Murato M, Quattrociocchi-Longe T, van Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol 1987; 87: 210-217.
140. Gundry SR, Drongowski RA, Klein MD, Coran AG. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist? Am Surgeon 1989; 55: 162-165.
141. Pifarre R, Babka R, Sullivan HJ et al. Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 378-381.
142. Consten EC, Henny CP, Eijsman L, Dongelmans DA, van Oers MH. The routine use of fresh frozen plasma in operations with cardiopulmonary bypass is not justified. J Thorac Cardiovasc Surg 1996; 112: 162-167.
143. Kasper SM, Giesecke T, Limpers P et al. Failure of autologous fresh frozen plasma to reduce blood loss and transfusion requirements in coronary artery bypass surgery. Anesthesiology 2001; 95: 81-86.
144. Levy JH, Despotis GJ, Olson PJ, Weisinger A, Szlam F. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery. Blood 1997; 90: 298.
145. Nielsen LE, Bell WR, Borkon AM, Neill CA. Extensive thrombus formation with heparin resistance during extracorporeal circulation. A new presentation of familial antithrombin III deficiency. Arc. Intern Med 1987; 147: 149-152.
146. Heindel SW, Mill MR, Freid EB et al. Fatal thrombosis associated with a hemi-fontan procedure, heparin-protamine reversal, and aprotinin. Anesthesiology 2001; 94: 369-371.
147. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003; 138: 128-134.
148. Ranucci M, Frigiola A, Menicanti L et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360.
149. Sodeck GH, Schillinger M, Ehrlich MP et al. Preoperative antithrombin III activity predicts outcome after surgical repair of acute type A aortic dissection. Atherosclerosis 2006; 186: 107-112.
150. Mammen EF, Koets MH, Washington BC et al. Hemostasis changes during cardiopulmonary bypass surgery. Sem Thromb Hemost 1985; 11: 281-292.
151. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Sem Thromb Hemost 1978; 5: 1-26.
152. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314: 1446-1448.
153. Clark RE, Beauchamp RA, Magrath RA et al. Comparison of bubble and membrane oxygenators in short and long perfusions. J Thorac Cardiovasc Surg 1979; 78: 655-666.
154. Journois D, Mauriat P, Pouard P et al. Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody. J Cardiothorac Vasc Anesth 1994; 8: 157-161.
155. Gelb AB, Roth RI, Levin J et al. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996; 106: 87-99.
156. Chan AK, Leaker M, Burrows FA et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77: 270-277.
157. Axford TC, Dearani JA, Ragno G et al. Safety and therapeutic effectiveness of reinfused shed blood after open heart surgery. Ann Thorac Surg 1994; 57: 615-622.
158. Boldt J, Schindler E, Knothe C et al. Does aprotinin influence endothelial-associated coagulation in cardiac surgery? J Cardiothorac Vasc Anesth 1994; 8: 527-531.
159. Boldt J, Zickmann B, Schindler E et al. Influence of aprotinin on the thrombomodulin/protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg 1994; 107: 1215-1221.
160. Turner-Gomes SO, Andrew M, Coles J et al. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992; 103: 87-97.
161. Gando S, Tedo I, Masio H, Goda Y, Kawahigashi H. Increased fibrinolytic activity during cardiopulmonary bypass is caused by activated protein C system. Masui 1994; 43: 912-914.
162. Boldt J, Knothe C, Schindler E et al. Thrombomodulin in pediatric cardiac surgery. Ann Thorac Surg 1994; 57: 1584-1589.
163. Boldt J, Kling D, Zickmann B et al. Acute plasmapheresis during cardiac surgery: volume replacement by crystalloids versus colloids. J Cardiothorac Anesth 1990; 4: 564-570.
164. Blauhut B, Harringer W, Bettelheim P et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-1091.
165. Chandler WL, Fitch JCK, Wall MH et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemostas 1995; 74: 1293-1297.
166. Muller N, Popov-Cenic S, Buttner W, Kladetzky RG, Egil H. Studies of fibrinolytic and coagulation factors during open heart surgery. II. Postoperative bleeding tendency and changes in the coagulation system. Thromb Res 1975; 7: 588-589.
167. Brooks DH, Bahnson HT. An outbreak of hemorrhage following cardiopulmonary bypass. Epidemiologic studies. J Thorac Cardiovasc Surg 1972; 63: 449-452.
168. Ellison N, Jobes DR. Effective Hemostasis in the Cardiac Surgical Patient: Current Status. In: Ellison N, Jobes DR, eds. Effective Hemostasis in Cardiac Surgery. WB Saunders, Philadelphia 1988 p 200.
169. Milam JD. Blood transfusion in heart surgery. Clin In Lab Med 1982; 2: 65-85.
170. Edmunds Jr LH, Ellison N, Colman RW et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982; 83: 805-812.
171. Gluszko P, Rucinski B, Musial J et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987; 252: 615-621.
172. Rinder CS, Mathew JP, Rinder HM et al. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991; 75: 563-570.
173. Rinder CS, Bohnert J, Rinder HM et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991; 75: 388-393.
174. Beurling-Harbury C, Galvan CA. Acquired decrease in platelet secretory ADP associated with increased post-operative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978; 52: 13-23.
175. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991; 324: 27-39.
176. Ray MJ, Hawson GA, Just SJ, McLachlan G, O'Brien M. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994; 57: 981-986.
177. Zilla P, Fasol R, Groscurth P et al. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 1989; 97: 379-388.
178. Wachfogel YT, Musial J, Jenkin B et al. Loss of platelet alpha 2-adrenergic receptors during simulated extracorporeal circulation: prevention with prostaglandin E1. J Lab Clin Med 1985; 105: 601-607.
179. Kestin AS, Valeri CR, Khuri SF et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107-117.
180. Addonizio Jr VP, Fisher CA, Kappa JR, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery 1987; 102: 796-807.
181. Ferraris VA, Ferraris SP, Singh A et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998; 65: 352-358.
182. Ereth MH, Nuttall GA, Klindworth JT et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997; 85: 259-264.
183. Despotis GJ, Levine V, Filos KS et al. Evaluation of a new, point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996; 85: 1311-1323.
184. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991; 38: 113-119.
185. George JN, Pickett EB, Saucerman S et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-348.
186. Dechavanne M, Ffrench M, Pages J et al. Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemost 1987; 57: 106-109.
187. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-797.
188. Sloand EM, Alyono D, Klein HG et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199-207.
189. Wildevuur CR, Eijsman L, Roozendaal KJ et al. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-538.
190. Teoh KH, Christakis GT, Weisel RD et al. Blood conservation with membrane oxygenators and dipyridamole. Ann Thorac Surg 1987; 44: 40-47.
191. Wachtfogel YT, Kucich U, Greenplate J et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-330.
192. Musial J, Niewiarowski S, Rucinski B et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation 1990; 82: 261-273.
193. Shore-Lesserson L, Fisher C, Ammar T, Sarier K, DePerio M. Comparison of hemoSTATUS with flow cytometric analysis of platelet function during cardiac surgical procedures. Anesth Analg 1997; 84: 108.
194. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993; 121: 579-587.
195. Rinder CS, Bonan JL, Rinder HM et al. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992; 79: 1201-1205.
196. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138.
197. Valeri CR, Feingold H, Cassidy G et al. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987; 205: 175-181.
198. Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998; 88: 1579-1585.
199. Valeri CR, Khabbaz K, Khuri SF et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg 1992; 104: 108-116.
200. Michelson AD, MacGregor H, Barnard MR et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71: 633-640.
201. John LC, Rees GM, Kovacs IB. Reduction of heparin binding to and inhibition of platelets by aprotinin. Ann Thorac Surg 1993; 55: 1175-1179.
202. Moorman RM, Zapol WM, Lowenstein E. Neutralization of Heparin Anticoagulation. In: Gravlee GP, ed. Cardiopulmonary bypass: Principles and Practice. Williams & Wilkens, Baltimore 1993, pp 381-382.